90,000 sq. ft. Expansion of Grand River Aseptic Manufacturing’s Finishing and Warehouse Center is Complete

February 27, 2024

GRAM Expands to Meet Growing Pharma Manufacturing Demands

 Grand River Aseptic Manufacturing (“GRAM”), a leading sterile injectable contract manufacturer of biologics, small molecules, and vaccines, announces the completion of its finishing and warehouse center expansion. The expansion added 90,000 sq. ft. to the existing 110,000 sq. ft., totaling 200,000 sq. ft. of sophisticated inspection, packaging, testing, and warehouse capabilities.


Grand River Aseptic Manufacturing is known for its state-of-the-art technology, world-class facilities, customer-centric team, and Annex 1 compliance. GRAM’s expansion of additional capabilities and systems supports an industry-wide need for syringe, cartridge, and vial filling and finishing, as well as the growth in advanced drug delivery systems.


“The increase in capabilities, capacity, and redundancy from this expansion sustains GRAM’s commitment to delivering quality products and supporting our partners with contract manufacturing that aligns with their needs,” said Tom Ross, President and CEO of Grand River Aseptic Manufacturing. “GRAM’s authenticity and transparency with our partners and component manufacturers allow us to serve with intention and continue our growth. I look forward to welcoming new and current customers to see all we offer.”


The 200,000 sq. ft. finishing and warehouse center will incorporate:

  • Four fully automated inspection systems (Korber and Optrel), eight semi-automated (Dabrico), and twelve manual inspection booths.
  • Four labeling and packing lines (Dividella, Uhlmann, Bausch + Ströbel, Marchesini) with future label and pack space.
  • Two autoclaves for product terminal sterilization.
  • QC analytical and sterility lab with sterility isolators (SKAN) to support lyophilized, biologics, and small molecule product testing.
  • Three -50°C walk-in freezers and three walk-in finished product (2-8°C and -20°C) refrigerated frozen units.
  • 30,000 sq. ft. reserved for additional syringe/cartridge filling lines.
  • Over 50,000 sq. ft. of material and finished product storage.


Grand River Aseptic Manufacturing’s finishing and warehouse center compliments its recently expanded cutting-edge filling facility, which includes four Bausch + Ströbel filling lines with SKAN isolator technology to manufacture clinical and commercial scale liquid vials, lyophilized vials, syringes, and cartridges. With over 100 million units of capacity, GRAM is ready to support pharma and biotech customers further


About Grand River Aseptic Manufacturing, Inc.
Grand River Aseptic Manufacturing, Inc.
, a prominent aseptic fill-finish contract development and manufacturing organization, delivers biologics, small molecules, and vaccine capabilities for liquid and lyophilized vials, syringes, and cartridges. Grand River Aseptic Manufacturing’s 300,000 sq. ft. of sophisticated GMP space supports customers’ drug products with advanced equipment, innovative technology, and a breadth of experienced team members.

RECENT ARTICLES

April 24, 2025
Prenuptial Patenting: Responsible Engagement with Engineering Firms
April 24, 2025
PharmOptima, a Poratge, Michigan-based preclinical contract research organization (CRO) is advancing drug discovery through its comprehensive suite of services. Specializing in in-vivo ADME/PK, ocular research, as well as regulated large and small molecule bioanalytical and ligand binding services, PharmOptima supports clients in optimizing drug development programs efficiently and effectively. With a staff averaging 11 years of industry experience and multiple individuals with advanced degrees, PharmOptima also boasts one of the most capable and engaging teams in the industry. The company collaborates with board-certified veterinary ophthalmologist Dr. Ryan Boyd, further enhancing its ocular research capabilities. PharmOptima's team of experts is dedicated to providing high-quality services to the pharmaceutical biotechnology industries. Looking ahead, PharmOptima scientists will be presenting posters at the 2025 The Association for Research in Vision and Ophthalmology (ARVO) conference, showcasing their latest research and innovations in ocular drug development. For more information visit www.pharmoptima.com .
April 24, 2025
Two bills, HB 4332 and HB 4333 were recently re-introduced that would prohibit pathogen gain-of-function (GoF) research. Given that the House is now Republican-led raises concerns for MichBio and others that the legislation might gain traction due to misinformation over biosafety and pandemic origins. MichBio opposes such broad legislative bans as they risk undermining critical scientific progress, public health preparedness, and economic innovation. GoF research has been instrumental in developing life-saving therapies and vaccines. For instance, viral vector-based gene therapies, such as Sarepta's Elevidys for Duchenne muscular dystrophy, and oncolytic virotherapies like Amgen's Imlygic for melanoma, rely on genetically modified viruses to deliver therapeutic genes or selectively destroy cancer cells. These advancements stem from GoF methodologies that enhance viral capabilities for therapeutic purposes. Moreover, GoF research has played a pivotal role in vaccine development. Examples like the AstraZeneca and Janssen COVID-19 vaccines and Merck's ERVEBO vaccine against Ebola employs a genetically modified virus to confer protection, underscore the public health benefits derived from GoF studies. ​ Contrary to concerns that GoF research operates without sufficient oversight, multiple layers of regulation are in place. Since 2017, the U.S. Department of Health and Human Services has implemented a framework to evaluate and guide funding decisions for GoF research, particularly those involving potential pandemic pathogens. This framework includes stringent safety protocols, risk assessments, and ethical reviews. ​ MichBio is most concerned that any legislative bans that broadly define and prohibit GoF research risk stifling innovation across various scientific fields. Such bans could inadvertently encompass research in virology, microbiology, molecular biology, and synthetic biology—disciplines vital for developing new therapies, sustainable agricultural practices, and environmental remediation technologies. ​ In turn, state-level bans on GoF research could have detrimental effects on local economies and academic institutions. Such a ban could impede research critical to understanding and combating diseases, leading to a loss of federal and philanthropic funding. This could hamper the growth of the Michigan's biotech and biomedical sectors. ​  MichBio advocates for a balanced approach that reinforces existing oversight mechanisms and fosters transparent, responsible research practices essential to safeguard both public health and scientific progress.